← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
CRANR
Crane Harbor Acquisition Corp. II
Valuation N/A
Financial Services
Price$0.19
Model IV—
P/IV—
Limited data — see page
CRAQ
Cal Redwood Acquisition Corp.
Valuation N/A
Financial Services
Price$10.39
Model IV—
P/IV—
Limited data — see page
CRAQR
Cal Redwood Acquisition Corp.
Valuation N/A
Financial Services
Price$0.15
Model IV—
P/IV—
Limited data — see page
CRBD
Corebridge Financial, Inc.
Valuation N/A
Financial Services Risk 40 · Elevated
Price$20.97
Model IV—
P/IV—
Limited data — see page
CRBP
Corbus Pharmaceuticals Holdings, Inc.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$6.92
Model IV—
P/IV—
Market implies +58.1%/yr vs model +15.0% · above model
CRBU
Caribou Biosciences, Inc.
Valuation N/A
Healthcare Risk 46 · Elevated
Price$1.27
Model IV—
P/IV—
Market implies +64.6%/yr vs model +3.8% · above model
CRCL
Circle Internet Group, Inc.
Valuation N/A
Financial Services Risk 50 · Elevated
Price$90.60
Model IV—
P/IV—
Market implies +77.5%/yr vs model +50.0% · above model
CRDF
Cardiff Oncology, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$1.21
Model IV—
P/IV—
Market implies +77.6%/yr vs model +13.4% · above model
CRDL
Cardiol Therapeutics Inc.
Valuation N/A
Healthcare Risk 36 · Moderate
Price$2.00
Model IV—
P/IV—
Limited data — see page
CRDO
Credo Technology Group Holding Ltd
Valuation N/A
Technology Risk 32 · Moderate
Price$162.95
Model IV—
P/IV—
Market implies +49.4%/yr vs model +50.0% · in line
CREG
Smart Powerr Corp.
Valuation N/A
Technology Risk 41 · Elevated
Price$0.18
Model IV—
P/IV—
Market implies -50.0%/yr vs model +12.0% · below model
CRF
CORNERSTONE TOTAL RETURN FUND INC
Valuation N/A
Unknown
Price$6.37
Model IV—
P/IV—
Limited data — see page
CRGO
Freightos Ltd
Valuation N/A
Industrials Risk 31 · Moderate
Price$1.19
Model IV—
P/IV—
Limited data — see page
CRMD
CorMedix Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$7.83
Model IV—
P/IV—
Limited data — see page
CRML
Critical Metals Corp.
Valuation N/A
Basic Materials Risk 37 · Moderate
Price$6.43
Model IV—
P/IV—
Limited data — see page
CRNC
Cerence Inc.
Valuation N/A
Technology Risk 53 · Elevated
Price$8.51
Model IV—
P/IV—
Market implies +16.9%/yr vs model -3.5% · above model
CRNX
Crinetics Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 36 · Moderate
Price$84.95
Model IV—
P/IV—
Market implies +71.6%/yr vs model +50.0% · above model
CRSP
CRISPR Therapeutics AG
Valuation N/A
Healthcare Risk 30 · Moderate
Price$51.72
Model IV—
P/IV—
Market implies +150.0%/yr vs model +2.0% · above model
CRT
CROSS TIMBERS ROYALTY TRUST
Valuation N/A
Financial Services
Price$11.99
Model IV—
P/IV—
Limited data — see page
CRVO
CervoMed Inc.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$2.57
Model IV—
P/IV—
Market implies +22.6%/yr vs model +15.0% · above model
CRVS
Corvus Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$12.91
Model IV—
P/IV—
Limited data — see page
CRWD
CrowdStrike Holdings, Inc.
Valuation N/A
Technology Risk 45 · Elevated
Price$206.74
Model IV—
P/IV—
Market implies +9.1%/yr vs model +34.9% · below model
CSAN
Cosan S.A.
Valuation N/A
Consumer Cyclical Risk 36 · Moderate
Price$2.73
Model IV—
P/IV—
Limited data — see page
CSHR
CoinShares PLC
Valuation N/A
Financial Services Risk 60 · High
Price$5.36
Model IV—
P/IV—
Limited data — see page
CSQ
CALAMOS STRATEGIC TOTAL RETURN FUND
Valuation N/A
Unknown
Price$20.83
Model IV—
P/IV—
Limited data — see page
CSWC
CAPITAL SOUTHWEST CORP
Valuation N/A
Unknown Risk 45 · Elevated
Price$24.19
Model IV—
P/IV—
Limited data — see page
CTAA
Clearthink 1 Acquisition Corp.
Valuation N/A
Financial Services Risk 43 · Elevated
Price$9.95
Model IV—
P/IV—
Limited data — see page
CTAAR
Clearthink 1 Acquisition Corp.
Valuation N/A
Financial Services Risk 35 · Moderate
Price$0.20
Model IV—
P/IV—
Limited data — see page
CTGO
Contango Silver & Gold Inc.
Valuation N/A
Basic Materials Risk 42 · Elevated
Price$18.31
Model IV—
P/IV—
Market implies +87.8%/yr vs model +5.0% · above model
CTMX
CytomX Therapeutics, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$3.29
Model IV—
P/IV—
Market implies +21.4%/yr vs model +19.5% · in line
CTNM
Contineum Therapeutics, Inc.
Valuation N/A
Healthcare Risk 47 · Elevated
Price$14.82
Model IV—
P/IV—
Market implies +18.4%/yr vs model +15.0% · above model
CTOR
CITIUS ONCOLOGY, INC.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$0.94
Model IV—
P/IV—
Limited data — see page
CTWO
COTWO ADVISORS PHYSICAL EUROPEAN CARBON ALLOWANCE TRUST
Valuation N/A
Financial Services Risk 28 · Moderate
Price$19.25
Model IV—
P/IV—
Limited data — see page
CTXR
Citius Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 38 · Moderate
Price$0.58
Model IV—
P/IV—
Market implies +67.7%/yr vs model +15.0% · above model
CUB
Lionheart Holdings
Valuation N/A
Financial Services
Price$10.87
Model IV—
P/IV—
Limited data — see page
CUBWU
Lionheart Holdings
Valuation N/A
Financial Services
Price$11.02
Model IV—
P/IV—
Limited data — see page
CUE
Cue Biopharma, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$30.55
Model IV—
P/IV—
Market implies +92.7%/yr vs model +16.4% · above model
CUPR
Cuprina Holdings (Cayman) LTD
Valuation N/A
Healthcare Risk 27 · Moderate
Price$2.93
Model IV—
P/IV—
Market implies +70.0%/yr vs model +15.0% · above model
CURR
Currenc Group Inc.
Valuation N/A
Technology Risk 34 · Moderate
Price$3.40
Model IV—
P/IV—
Market implies +18.5%/yr vs model -3.4% · above model
CURX
Curanex Pharmaceuticals Inc
Valuation N/A
Healthcare Risk 27 · Moderate
Price$4.55
Model IV—
P/IV—
Limited data — see page
CV
CapsoVision, Inc
Valuation N/A
Healthcare Risk 40 · Elevated
Price$6.60
Model IV—
P/IV—
Market implies +19.1%/yr vs model +15.3% · above model
CVE
CENOVUS ENERGY INC.
Valuation N/A
Energy Risk 33 · Moderate
Price$33.27
Model IV—
P/IV—
Limited data — see page
CVKD
Cadrenal Therapeutics, Inc.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$1.09
Model IV—
P/IV—
Limited data — see page
CVLT
COMMVAULT SYSTEMS INC
Valuation N/A
Technology Risk 45 · Elevated
Price$143.30
Model IV—
P/IV—
Market implies +23.6%/yr vs model +12.9% · above model
CVM
CEL SCI CORP
Valuation N/A
Healthcare Risk 27 · Moderate
Price$1.49
Model IV—
P/IV—
Limited data — see page
CVV
CVD EQUIPMENT CORP
Valuation N/A
Industrials Risk 42 · Elevated
Price$4.68
Model IV—
P/IV—
Market implies +55.0%/yr vs model +11.9% · above model
CWAN
Clearwater Analytics Holdings, Inc.
Valuation N/A
Technology Risk 39 · Moderate
Price$24.56
Model IV—
P/IV—
Market implies +35.9%/yr vs model +25.0% · above model
CWD
CaliberCos Inc.
Valuation N/A
Real Estate Risk 33 · Moderate
Price$0.51
Model IV—
P/IV—
Market implies -20.9%/yr vs model +2.0% · below model
CWH
Camping World Holdings, Inc.
Valuation N/A
Consumer Cyclical
Price$5.76
Model IV—
P/IV—
Limited data — see page
CX
CEMEX SAB DE CV
Valuation N/A
Industrials Risk 32 · Moderate
Price$10.19
Model IV—
P/IV—
Limited data — see page
CXAI
CXApp Inc.
Valuation N/A
Technology Risk 34 · Moderate
Price$2.84
Model IV—
P/IV—
Market implies +71.9%/yr vs model +15.0% · above model
CXE
MFS HIGH INCOME MUNICIPAL TRUST
Valuation N/A
Unknown
Price$4.10
Model IV—
P/IV—
Limited data — see page
CXH
MFS INVESTMENT GRADE MUNICIPAL TRUST
Valuation N/A
Unknown
Price$8.48
Model IV—
P/IV—
Limited data — see page
CXW
CoreCivic, Inc.
Valuation N/A
Financial Services Risk 40 · Elevated
Price$34.93
Model IV—
P/IV—
Limited data — see page
CYAB
CYABRA, INC.
Valuation N/A
Technology Risk 35 · Moderate
Price$0.33
Model IV—
P/IV—
Limited data — see page
CYCN
Cyclerion Therapeutics, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$23.94
Model IV—
P/IV—
Market implies +106.6%/yr vs model +2.0% · above model
CYD
CHINA YUCHAI INTERNATIONAL LTD
Valuation N/A
Industrials Risk 31 · Moderate
Price$35.82
Model IV—
P/IV—
Limited data — see page
CYN
Cyngn Inc.
Valuation N/A
Technology Risk 36 · Moderate
Price$0.79
Model IV—
P/IV—
Market implies +53.5%/yr vs model +15.0% · above model
CYPH
CYPHERPUNK TECHNOLOGIES INC.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$2.27
Model IV—
P/IV—
Market implies +74.8%/yr vs model +15.0% · above model
CYRX
Cryoport, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$15.55
Model IV—
P/IV—
Market implies +47.6%/yr vs model +2.0% · above model